Medtronic, Inc.

David E Linde

Scott R Stanslaski

Timothy J Denison

David L Carlson

Jonathon E Giftakis

Benjamin P Isaacson

Duane L Bourget

Robert S Raike

Pedram Afshar

Peng Cong

Paul H Stypulkowski

Thomas Adamski

Randy M Jensen

Nicholas D Buse

Mae Eng

Christopher L Pulliam

Thaddeus S Brink

Rene A Molina

Abbey Beuning Holt Becker

Thomas L Chouinard

Robert Devine

Jeffrey Herron

Caleb C Zarns

Disclosed herein are methods, systems, and computer-readable media for blocking attempts at runtime redirection and attempts to change memory permissions during runtime. The present disclosure describes features that enable runtime detection of an attempt to redirect routines or change memory permissions, and determining whether to allow or deny the attempt. Such features may include changing memory write permissions on memory segments, such as those segments used by dynamic loaders after call associations have been saved or otherwise created. Other features may include swapping the addresses of system routines (e.g., open, read, write, close, etc.) to new routines that perform the same function as well as additional functionality configured to detect attempts to redirect or change memory permissions. Once detected by the new routine during runtime, a determination may be made to deny or allow the call based on a policy.

Blocking routine redirection

An example method includes determining, by an implantable medical device (IMD), an electrode of a plurality of electrodes of a lead to be used to deliver electrical stimulation to a patient at a particular time; selecting, by the IMD and based on the determined electrode, a set of electrodes of the plurality of electrodes; and sensing, by the IMD and via the selected set of electrodes, electrical signals of the patient at the particular time.

Dynamically optimized neural sensing

A medical device or system of medical devices can be configured to detect an indicator of a symptom in a patient; in response to detecting the indicator of the symptom in the patient, deliver to the patient a first stimulation therapy; and in response to determining that the indicator of the symptom has been present for more than a threshold amount of time after beginning to deliver the first stimulation therapy a second stimulation therapy different than the first stimulation therapy.

Multi-target adaptive neurostimulation therapy control

In some examples of selecting a target therapy delivery site for treating a patient condition, a relatively high frequency electrical stimulation signal is delivered to at least two areas within a first region (e.g., an anterior nucleus of the thalamus) of a brain of a patient, and changes in brain activity (e.g., as indicated by bioelectrical brain signals) within a second region (e.g., a hippocampus) of the brain of the patient in response to the delivered stimulation are determined. The target therapy delivery site, an electrode combination, or both, may be selected based on the changes in brain activity.

Identification of compromised components in a medical system

Devices, systems, and techniques are described for transitioning between different groups of electrical stimulation programs. For example, a system may control delivery of second electrical stimulation defined by one or more second programs of a second group of stimulation programs on a time-interleaved basis with first electrical stimulation defined by one or more first programs of the first group of stimulation programs. The system may change a first ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a first period of time to a second ratio of the one or more first programs used to define the first electrical stimulation to the one or more second programs used to define the second electrical stimulation delivered within a second period of time.

Changing electrical stimulation

The disclosure describes a method and system or controlling symptoms of patients suffering from Parkinson's Disease. In some examples, one or more biomarkers indicative of a patient's present symptoms are determined. The biomarkers may be used to control therapy delivered to the patient in a closed-loop manner. In addition, biomarkers may be used as an indication of therapy effectiveness.

Movement disorder symptom control

Various embodiments concern identifying a biomarker in the presence of electrical stimulation. Various embodiments concern delivering electrical stimulation to a patient and sensing one or more signals while the electrical stimulation is being delivered, the one or more signals including data indicative of physiological activity. Various embodiments further include determining an intensity of the electrical stimulation and determining whether the data indicates the presence of a biomarker based on a variable threshold, the variable threshold being variable based on the intensity of the electrical stimulation. Various embodiments concern determining a relationship between stimulation intensity and a biomarker parameter to determine the variability of the variable threshold.

Method and apparatus for detecting a biomarker in the presence of electrical stimulation

This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a chopper amplifier to amplify an input signal prior to sampling the signal. In some examples, the techniques for controlling spectral aggressors may include generating a chopper-stabilized amplified version of an input signal based on a chopper frequency, sampling the chopper-stabilized amplified version of the input signal at a sampling rate to generate a sampled signal, and analyzing a target frequency band of the sampled signal. The chopper frequency and the sampling rate may cause spectral interference that is generated due to the chopper frequency to occur in the sampled signal at one or more frequencies that are outside of the target frequency band of the sampled signal. The techniques for controlling spectral aggressors may reduce the noise caused by the chopper frequency in the resulting sampled signal, thereby improving the quality of the signal.

Control of spectral agressors in a physiological signal monitoring device

This disclosure describes techniques for controlling spectral aggressors in a sensing device that uses a low power sleep mode to manage the power consumed by the device. In some examples, the techniques for controlling spectral aggressors may include configuring one or more of an algorithm processing rate for a processor, a buffering rate for the processor, a sampling rate for an analog-to-digital converter, an execution unit processing rate for the processor, and an algorithm subdivision factor for the processor such that spectral interference caused by a sleep cycle rate of the processor occurs outside of one or more target frequency bands of a sampled signal. The techniques of this disclosure may be used to reduce noise in a sensing system that uses a low power sleep mode to manage the power consumed by the device.

Control of spectral agressors in a physiological signal montoring device

This disclosure describes a state machine framework for programming closed-loop algorithms that control the delivery of therapy to a patient by an implantable medical device (IMD). The state machine framework may use one or more programmable state parameters to define at least part of a structure of a state machine that generates one or more therapy decisions based on one or more sensed states of the patient. The state machine framework may include a state machine runtime environment that executes on an IMD and that is configurable to implement a variety of different state machines depending on programmable state parameters that are received from an external device. The techniques of this disclosure may, in some cases, allow IMD developers and/or users to program, change, and/or download new closed-loop control policy algorithms during the lifespan of the IMD without requiring new firmware code to be downloaded onto the IMD.

Growing community of inventors

Corcoran, MN, United States of America

David E Linde